1. Introduction {#sec-1}
===============

Coronoviruses have been reported as causes of mild and moderate respiratory infections forover 50 years \[1\]. Even though this group of viruses have been isolated from many different animals, bats are accepted major natural reservoir of coronaviruses \[2,3\].

Four human coronavirus, 229E, HKU1, NL63 and OC43, are known as causes of common cold in humans \[1\]. However, recently-detected coronaviruses, SARS CoV (2002), MERS-CoV (2012) completely altered all known approaches about this virus group because these viruses caused severe acute respiratory infections and nosocomial outbreaks. In the end of 2019, a novel coronavirus, now known as SARS-CoV-2 (2019), suddenly emerged in Wuhan, China. The World Health Organization declared that the epidemic is a public health emergency of international concern on January 31, 2020. As of April 16, 2020, the emerging coronavirus infection, COVID-19, has been spreading worldwide, causing over 2 million cases and over 137 thousand of death.

In as much as this disease recently taken a significant place in our daily practice, as a new group of respiratory diseases, due to their higher rates of transmissibility, hospitalization, intensive care unit admission, severity of disease, mortality and so on, we should pay more attention than past to prevention and treatment of coronavirus infection.

2. Origin of the SARS CoV-2 virus {#sec-2}
=================================

The first cases of coronavirus disease COVID-19 were directly related to an animal market in Wuhan, China. Early investigations suggested that the origin of SARSCoV-2 may be bats. Zhou et al. demonstrate that SARS CoV-2 possesses 96% nucleotide identity with a bat coronavirus, for instance BetaCoV/RaTG13/2013 \[4\].

3. Epidemic curve of infection {#sec-3}
==============================

An epidemic curve of infection is a statistical chart used in epidemiology to visualize the onset of the coronavirus outbreak. In an epidemic curve, there are three zones: increasing, plateau, and declining phases.

Increasing phase: This period is affected by many different parameters such as country demographics, age distribution, preparedness of health system to an outbreak, implementation of some preventive measures, country reaction time to a pandemic, reaction of society to new implementing rules. Different countries can exhibit quite different curve patterns and these facts could complicate to make any assumption about pandemic pattern for a country (Figure 1). However, it seems that this period takes generally 3 or 4 weeks for COVID-19 (Table 1).

![Daily new confirmed COVID-19 cases per million people for some contries (Source: OurWorld in Data, accessed 13 April 2020).](turkjmedsci-50-563-fig001){#F1}

###### 

Dates of epidemic curve (dates for case per million was used)\*.

  ------------- ------------------------- ------------------------ ---------------------------- ------------------------------ ------------------------------------- ---------------------------------- ------------------------------------
   Countries    Onset of outbreak(date)   Onset of plateau(date)   End of plateau phase(date)   End of declining phase(date)   Duration of increasing period (day)   Duration of plateau period (day)   Duration of declining period (day)
  China         19.01.2020                05.02.2020               19.02.2020                   3.03.2020                      17                                    14                                 13
  Italy         22.02.2020                22.03.2020               08.04.2020                   N/A                            29                                    17                                 N/A
  Germany       28.02.2020                20.03.2020               10.04.2020                   N/A                            21                                    21                                 N/A
  France        28.02.2020                24.03.2020               11.04.2020                   N/A                            25                                    18                                 N/A
  Spain         27.02.2020                26.03.2020               9.04.2020                    N/A                            28                                    14                                 N/A
  Turkey        16.03.2020                11.04.2020               N/A                          N/A                            26                                                                       N/A
  South Korea   19.02.2020                29.02.2020               10.03.2020                   N/A                            10                                    10                                 N/A
  Belgiun       03.03.2020                27.03.2020               12.04.2020                   N/A                            24                                    16                                 N/A
  Austria       22.02.2020                20.03.2020               04.04.2020                   N/A                            27                                    15                                 N/A
  Australia     05.03.2020                22.03.2020               04.04.2020                   N/A                            17                                    13                                 N/A
  Malasia       02.03.2020                16.03.2020               11.04.2020                   N/A                            14                                    26                                 N/A
  ------------- ------------------------- ------------------------ ---------------------------- ------------------------------ ------------------------------------- ---------------------------------- ------------------------------------

\*According to data's of 13.04.2020.

Plateau phase: At this phase disease incidence is stable. According to daily country reports it takes 2 or 3 weeks for COVID-19 (Table1).

Decreasing phase: Today we have only China's data about this phase (Figure 2), showing that 2 or 3 weeks later disease activity could be detected very low levels.

![Daily new confirmed COVID-19 cases per million people for China (Source: OurWorld in Data, accessed 13 April 2020).](turkjmedsci-50-563-fig002){#F2}

4. Incubation period {#sec-4}
====================

The incubation period of COVID-19 was defined 5.2 days (95% CI, 4.1--12.5 days), 5.1 days (95% CI, 4.5 to 5.8 days) and 4 days in three separate study \[5,6\]. However, in a familial cluster of 5 patients, this period was reported between 1 and 19 days \[7\]. These data show that the incubation period of COVID-19 was similar to MERS and SARS and it's a bit longer than influenza \[8\].

5. Severity of infection {#sec-5}
========================

COVID-19 has been reported form all aged patients. Severity of infection could be varied from asymptomatic infection to critical disease. Clinical severity of COVID-19 was defined in 5 groups as asymptomatic, mild, moderate, severe, and critical. Diagnostic criteria of these groups were as follows \[9, 10\];

1\. Asymptomatic infection: Without any clinical sign of symptoms with positive SARSCoV-2 PCR test.

2\. Mild: Symptoms of acute upper respiratory tract infection, including fever, fatigue, myalgia, cough, sore throat, runny nose, and sneezing without pneumonia.

3\. Moderate: With pneumonia, frequent fever and cough; some may have wheezing, but no obvious hypoxemia such as shortness of breath.

4\. Severe: Rapid progression around 1 week, dyspnea, with central cyanosis, oxygen saturation less than 92%, with other manifestations of hypoxemia.

5\. Critical: Patients with acute respiratory distress syndrome (ARDS) or respiratory failure, shock, multiple organ dysfunction.

This clinical classification is also important because it gives some clues about prognosis and mortality of COVID-19. Most COVID-19 cases (81%) were classified as mild or moderate disease in adults, and in children most cases were mild. \[9,11,12\]. In critical cases mortality could be as higher as 50% in adults \[9,11\].

5.1. Asymptomatic infection {#sec-5-1}
---------------------------

Asymptomatic infection has a special importance as a source of disease in the community. Especially, asymptomatic infants and children may take an important role in human-to-human transmission \[13\]. Dong and colleagues report that over 90% of pediatric patients could be asymptomatic, or could have mild or moderate disease \[11\]. It seems that asymptomatic infection could be detected at every age, although it was frequent at younger ages \[14\]. These asymptomatic patients could cause familial clusters \[15\]. According to Tian et al., asymptomatic infection rate was 5%, whereas in Diamond Princess Cruise Ship berthed at Tokyo Bay, Japan, it was nearly 18% \[16,17\]. Among a total of 72,314 China's cases, 889 were classified as asymptomatic (1%) \[9\]. However, we need more accurate numbers before making some assumption about its public health importance.

6. Route of transmission {#sec-6}
========================

In spite of the fact that some animals are thought as origins of the virus, a major transmission mode for SARS CoV-2 is human-to-human transmission like SARS CoV and MERS CoV. Accepted transmission routes of COVID-19 are droplet and contact transmission \[18\]. Nevertheless, explaining or excluding of other possible transmission routes is necessary for controlling disease in the community.

6.1. Airborne transmission {#sec-6-1}
--------------------------

Current evidence shows that SARS CoV-2 was detected in air samples for up to 3 h in experimental models \[19\]. Gou et al. found that air samples were positive in many different sites of wards \[20\]. However, when Cheng et al. collected 8 air samples at a distance of 10 cm from the patient's chin with or without wearing a surgical mask, they were not able to detect SARS CoV-2 \[21\]. Another study, although some environmental samples were positive for SARS CoV-2, all air samples were negative \[22\]. In a study from Iran, authors reported that all air samples collected 5 m around the patients were negative \[23\].

There are some limitations in these studies where different patients and methods were included; in which stage of disease these samples were collected, or what kind of procedures were performed. Today, we have not known yet whether detected SARS CoV-2 in air samples are viable or not, or whether detected viral loads are high enough to cause COVID-19. It is important to realize here that prior to answering such questions and obtain some strong evidence, taking airborne precautions for aerosol producing process seems to be logical.

6.2. Fecal transmission {#sec-6-2}
-----------------------

Fecal transmission is another unanswered question about COVID-19. Presence of patients with diarrhea \[6\], finding of fecal samples positive for SARS CoV by RT-PCR \[24,25\] and detection of live virus in stool at least one study \[25\], suggest that stool is infectious even though it has not been verified by other studies \[24\]. Detection of SARS CoV-2 RNA in patients' fecal samples with negative respiratory tract samples for a mean of 11 days might be important \[26\]. Even if gastrointestinal involvement or digested sputum was the origin of virus existence in the stool, this fact gives another reason to emphasize good personal hygiene. Possibility of fecal transmission remains unanswered until viable virus is detected in stool samples and new data is available to prove oral-fecal transmission, which affect procedures for quarantine, hospitalization and self-isolation practices.

6.3. Maternal fetal transmission {#sec-6-3}
--------------------------------

Intrauterine or transplacental transmission from infected pregnant women to their fetuses is another important point for transmission. According to a study about analyzing of 38 pregnant women with COVID-19, there were no signs of intrauterine transmission of SARS CoV-2 from mothers to their fetuses \[27\]. Studies also emphasized that the course of COVID-19 was normal in pregnant women as opposed to those of SARS and MERS \[27,28\]. Another study also reviewed that we have no definitive evidence of vertical transmission \[29\].

7. Transmission period {#sec-7}
======================

People infected with SARS CoV-2 can be contagious prior to onset of symptoms. In a study, 13% of patients were contagious before onset of symptoms \[30\]. In a familial cluster, 3 of 8 laboratory-confirmed patients were asymptomatic \[31\]. Presymptomatic transmission would be a challenge to contact tracing \[32\]. These kind of reports show that asymptomatic carriers emerge as an important target group to be taken into consideration in the control of the disease.

Viral shedding might be longer than previously thought. In a retrospective multicenter cohort study of 191 adult patients, the median duration of viral shedding was found to be 20 days (IQR 17.0--24.0) and the longest observed duration of viral shedding in survivors was 37 days \[33\].A study of postdischarge surveillance of patients after clinical recovery, two patients were found positive \[34\].

8. Susceptible ages {#sec-8}
===================

Although COVID-19 was reported from every aged patient, patients with advanced age seem more susceptible to infection. An early report shows that the most affected age group was middle ages (Table 2). Among children and young adults, infection rates were very low and it changed between 0.8%--4.0%. In addition, asymptomatic infection rate is quite high in this ages.

###### 

Confirmed COVID-19 cases by age groups.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------ ------------ ----------------- --------------- ----------------- ------------ ------------ ------ ------------ ------ ------------ ------
                                                                                                                                                                                                                                                                                                                                 Spain\*      Canada\*\*   Nederland\*\*\*   China\*\*\*\*   Italy\*\*\*\*\*   Germany^Y^                                                        
                                                                                                                                                                                                                                                                                                                                 Total case   \%           Total case        \%              Total case        \%           Total case   \%     Total case   \%     Total case   \%
  \<20                                                                                                                                                                                                                                                                                                                           741          0.8          220               4               173               1.1          965          2      1868         1.5    2624         2.8
  20--29                                                                                                                                                                                                                                                                                                                         4,629        5.2          658               13              974               6.2          3619         8      33,248       26.7   66,896       70.3
  30--39                                                                                                                                                                                                                                                                                                                         8,761        9.9          847               16              1251              8            38,680       87                                      
  40--49                                                                                                                                                                                                                                                                                                                         13,421       15.2         881               17              1582              10.1                                                              
  50--59                                                                                                                                                                                                                                                                                                                         16,577       18.8         1023              19              2590              16.5         44,581       35.8                                    
  60--69                                                                                                                                                                                                                                                                                                                         14,933       16.9         855               16              2450              15.5         18,307       19.3                                    
  70--79                                                                                                                                                                                                                                                                                                                         14,300       16.2         468               9               3013              19.8         44,830       36                                      
  80--89                                                                                                                                                                                                                                                                                                                         14,828       16.8         309               6               3550              22.8         1408         3      7357         7.7                 
  Total                                                                                                                                                                                                                                                                                                                          88,190       100.0        5261                              15723             100          72,314       100    124,527      100    94,850       100
  \* Spain (2020), Actualización nº 67. Enfermedad por el coronavirus (COVID-19) \[online\]. Website https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_67_COVID-19.pdf \[accessed 06 April 2020\].                                                                                                                                                                                                                    
  \*\* Canada (2020). Age distribution of COVID-19 cases (n=5,261) in Canada \[online\]. Website https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/health-professionals/epidemiological-summary-covid-19-cases.html\#a3 \[accessed 01 April 2020\].                                                                                                                                                                                      
  \*\*\*Nederland (2020). Epidemiologische situatie COVID-19 in Nederland 3 april 2020 \[online\]. Website https://www.rivm.nl/documenten/epidemiologische-situatie-covid-19-in-nederland-3-april-2020 \[accessed 03 April 2020\].                                                                                                                                                                                                                                               
  \*\*\*\* China (2020). Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China \[online\]. Website  https://jamanetwork.com/journals/jama/fullarticle/2762130 \[accessed 00 Month Year\].                                                                                                                                                                                                                                      
  \*\*\*\*\* Italy (2020). Integrated surveillance of COVID-19 in Italy \[online\]. Website https://www.epicentro.iss.it/en/coronavirus/bollettino/Infografica_6aprile%20ENG.pdf \[accessed 00 Month Year\].                                                                                                                                                                                                                                                                     
  ^Y^Germany (2020). Coronavirus disease 2019 (COVID-19) daily sSituation report of the Robert Koch Institute 06/04/2020-updated status for Germany \[online\]. Website https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/Situationsberichte/2020-04-06-en.pdf?\_\_blob=publicationFile \[accessed 00 Month Year\].                                                                                                                                                   
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------ ------------ ----------------- --------------- ----------------- ------------ ------------ ------ ------------ ------ ------------ ------

9. Transmissibility and R0 {#sec-9}
==========================

Early reports from China show that a reproductive number for COVID-19 was 2.2 to 2.7 days \[5\]. This means that the number of infected person will be doubled every 6--7 day. A reproductive number of the outbreak on the Diamond Princess Cruise Ship also supports this preliminary data \[35\]. However, Sanche et al. found that a serial interval was 5.7 days (95% CI, 3.8--8.9 days) \[36\]. In another study which prefer to use real-time reproduction number (Rt) instead of basic reproduction number (R0), Yuan et al. showed that their Rt values for Italy, Germany, France and Spain were 3.1, 4.43, 6.56, and 3.95, respectively \[37\]. Liu et al. found that average R0 was 3.8 (1.4--6.49) in their review of 14 studies \[38\]. This study also showed that even in the same geographic region, different Ro values can be calculated by using different methods and assumptions. It seems that we need more data to determine more accurate R0 value.

10. Case fatality rate {#sec-10}
======================

Overall case fatality rate was 6.3 according to WHO situation report as of April 13, 2020 \[39\]. Nevertheless, a remarkable difference in mortality rates was also noted between countries as given Table 3. It was noted that this rate is extremely higher in country with older-aged populations. In Italy, the median age of those died from COVID-19 was 78 years, whilst the median age of patients was 62 \[40\]. In Turkey, the current case fatality rate is 2.1% which is a significant issue to bear in mind. Mortality associated with COVID-19 is a multifactorial process and underlying diseases and health care burden as well as ages could be related to higher mortality \[41\].

###### 

Total confirmed cases, deaths and case fatality rate of some countries\*.

  Reporting country    Total confirmed cases   Total deaths   Case fatality rate
  -------------------- ----------------------- -------------- --------------------
  France               94,382                  14,374         15.23
  Italy                156,363                 19,901         12.73
  The United Kingdom   84,283                  10,612         12.59
  Belgium              29,647                  3600           12.14
  Netherlands          25,587                  2737           10.70
  Spain                166,019                 16,972         10.22
  Sweden               10,483                  899            8.58
  İran                 71,686                  4474           6.24
  Brazil               20,727                  1124           5.42
  China                83,597                  3351           4.01
  USA                  524,514                 20,444         3.90
  Switzerland          25,220                  858            3.40
  Portugal             16,585                  504            3.04
  Canada               23,702                  674            2.84
  Austria              13,937                  350            2.51
  Germany              123,016                 2799           2.28
  Turkey               56,956                  1198           2.10
  Republic of Korea    10,537                  217            2.06
  Israel               10,878                  103            0.95
  Russian Federation   18,328                  148            0.81
  Grand total          1,773,084               111,652        6.30

\*World Healt Organization (2020). Coronavirus disease 2019 (COVID-19) Situation Report--84 \[online\]. Website https://www.who.int/docs/default-source/coronaviruse/situationreports/ 20200413-sitrep-84-covid-19.pdf?sfvrsn=44f511ab_2 \[accessed 13 April 2020\].

10.1. Mortality by ages {#sec-10-1}
-----------------------

Increasing of mortality with advanced age is now a well-known fact. It is also well known that success in prevention of COVID-19 among these age groups directly determines th emortality rate in countries. Early Chinese reports showed that mortality rate could be 3 times higher in older patients especially those at age over 80 \[9\]. In an Italian study, ICU mortality was 26% whereas it was 36% after 65 of ages \[42\]. Demonstration of median days between onset of symptoms to death was shorter in older patients which is another important point \[43\].

As of April 7, 2020 in Italy, 83% of all COVID-19 related deaths were reported in an age group over 70 years \[44\]. In a Korean study, although overall mortality rate was 0.9%, mortality rate in those aged 80 and over was 9.3% \[45\]. Similar results were also reported form USA \[45\].

10.2. Risks for disease and death {#sec-10-2}
=================================

Disease progression can be rapid and the median survival time can be as short as 5 days in advanced aged patients \[28\].

In a metaanalysis which evaluated 46,248 patients from eight studies, most prevalent comorbidities were hypertension, diabetes mellitus, cardiovascular diseases and respiratory diseases. Another finding of this study was that these comorbidities were more likely detected in severe patients \[47\]. Another metaanalysis showed that hypertension, cardiovascular diseases, diabetes mellitus, smoking, chronic obstructive pulmonary disease, malignancy, and chronic kidney disease were most frequently detected underlying diseases among hospitalized patients \[48\].

In a summary report form China CDC, preexisting comorbid condition can increase fatality rate by 10.5% for cardiovascular disease, 7.3% for diabetes, 6.3% for chronic respiratory disease, 6.0% for hypertension, and 5.6% for cancer \[9\].

According to the Italian weekly report on death from COVID-19, most frequently detected comorbidities were hypertension, diabetes mellitus, ischemic heart disease, and chronic renal failure as 72%, 31.5%, 27.4%, and 23.5%, respectively. This report showed that patients without any comorbidities accounted for only 2.8% of those died from COVID-19 \[40\].

In a pooled analysis, risk of severe disease and mortality was higher in hypertensive patients nearly 2.5 fold increases especially among advanced aged individuals \[49\].

12. Conclusion {#sec-12}
==============

Every day we learn new data about the current pandemic of COVID-19. Since the outbreak has not been over yet, the updates should be followed closely to monitor the disease and the risk factors as well as therapy modalities.
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